Use of oral antidiabetic drugs in the treatment of maturity-onset diabetes of the young: A mini review

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F18%3A43915114" target="_blank" >RIV/00216208:11120/18:43915114 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00216208:11130/18:10371453 RIV/00064173:_____/18:N0000022 RIV/00064203:_____/18:10371453

Výsledek na webu

<a href="https://doi.org/10.1002/dmrr.2940" target="_blank" >https://doi.org/10.1002/dmrr.2940</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/dmrr.2940" target="_blank" >10.1002/dmrr.2940</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Use of oral antidiabetic drugs in the treatment of maturity-onset diabetes of the young: A mini review

Popis výsledku v původním jazyce

Background: MODY (Maturity-onset diabetes of the young) is a genetically linked group of clinically heterogeneous subtypes of diabetes. Roughly 5% of people with diabetes mellitus diagnosed prior to age 45 have MODY diabetes, the majority of whom have been erroneously diagnosed as patients with either Type 1 or Type 2 diabetes and, as a result, have been improperly treated. Genetic identification of MODY diabetes and its subtypes allows proper treatment and enables clinicians to switch many patients to oral antidiabetic agents, mainly sulphonylureas. However, some new classes of oral diabetic drugs have also been tested and found to be effective in MODY patients. Methods: We have searched for research articles and case reports written in full-text English or with an English abstract, using the following keywords: MODY and oral antidiabetic* in the databases Cohrane Library, PubMed and Science Direct. Results: Therapeutic options using currently standardized oral antidiabetic drugs (mainly sulphonylureas), as well as more experimental treatment with other classes of oral antidiabetic drugs in different types of MODY are discussed, with special focus on the therapy of the most common MODY subtypes, including specific conditions as pregnancy. Conclusion: This review article summarizes the currently available information about oral antidiabetic treatment available for patients with MODY diabetes.

Název v anglickém jazyce

Use of oral antidiabetic drugs in the treatment of maturity-onset diabetes of the young: A mini review

Popis výsledku anglicky

Background: MODY (Maturity-onset diabetes of the young) is a genetically linked group of clinically heterogeneous subtypes of diabetes. Roughly 5% of people with diabetes mellitus diagnosed prior to age 45 have MODY diabetes, the majority of whom have been erroneously diagnosed as patients with either Type 1 or Type 2 diabetes and, as a result, have been improperly treated. Genetic identification of MODY diabetes and its subtypes allows proper treatment and enables clinicians to switch many patients to oral antidiabetic agents, mainly sulphonylureas. However, some new classes of oral diabetic drugs have also been tested and found to be effective in MODY patients. Methods: We have searched for research articles and case reports written in full-text English or with an English abstract, using the following keywords: MODY and oral antidiabetic* in the databases Cohrane Library, PubMed and Science Direct. Results: Therapeutic options using currently standardized oral antidiabetic drugs (mainly sulphonylureas), as well as more experimental treatment with other classes of oral antidiabetic drugs in different types of MODY are discussed, with special focus on the therapy of the most common MODY subtypes, including specific conditions as pregnancy. Conclusion: This review article summarizes the currently available information about oral antidiabetic treatment available for patients with MODY diabetes.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30202 - Endocrinology and metabolism (including diabetes, hormones)

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2018

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Diabetes/Metabolism Research and Reviews

ISSN

1520-7560

e-ISSN

—

Svazek periodika

34

Číslo periodika v rámci svazku

1

Stát vydavatele periodika

GB - Spojené království Velké Británie a Severního Irska

Počet stran výsledku

6

Strana od-do

"Article e2940"

Kód UT WoS článku

000422967700004

EID výsledku v databázi Scopus

2-s2.0-85030645323